{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:00:34Z","timestamp":1785128434966,"version":"3.55.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-small cell lung cancer (NSCLC) accounts for 85% of new lung cancer diagnoses. Although docetaxel\u2013nintedanib combination therapy improves survival in previously treated NSCLC, its real-world safety profile has not been comprehensively characterized. This study aimed to comprehensively characterize the real-world safety profile of docetaxel, nintedanib, and their combination in patients with NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrieved adverse drug reaction(ADR) reports associated with docetaxel, nintedanib monotherapy and their combination in NSCLC patients from the FAERS database. Disproportionality analyses using the Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) were performed, followed by clinical priority scoring and time-to-onset analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 54, 66, and 78 significant PT-level safety signals were identified for docetaxel monotherapy, nintedanib monotherapy, and their combination therapy, respectively, and all signals remained significant after BH-FDR correction (P&amp;lt;0.05). Compared with either monotherapy, the combination regimen demonstrated a broader toxicity spectrum with relatively greater reporting of hematologic, gastrointestinal, infectious, and hepatobiliary adverse reactions. Combination therapy showed disproportionately strong signals for mucosal infection (ROR\u00a0=\u00a0343.76, IC\u00a0=\u00a08.40, p&amp;lt;0.001), metastases to adrenals (ROR\u00a0=\u00a090.15, IC\u00a0=\u00a06.49, p&amp;lt;0.001) and portal vein thrombosis (ROR\u00a0=\u00a028.43, IC\u00a0=\u00a04.83, p&amp;lt;0.001). Docetaxel monotherapy was predominantly associated with skin and psychiatric disorders, whereas nintedanib monotherapy was predominantly associated with hepatic injury and thromboembolic events. Clinical prioritization identified febrile neutropenia, intestinal perforation, and sepsis as the highest-priority adverse events in the combination group. Median time-to-onset was shorter for combination therapy than for docetaxel or nintedanib monotherapy (22.5 vs. 34.5 and 34.5 days, Log-rank p&amp;lt;0.001). Weibull analysis indicated an early-failure pattern (\u03b2 &amp;lt; 1) for all three regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides a comprehensive real-world comparison of the safety profiles of docetaxel, nintedanib, and their combination, identifying distinct toxicity patterns and clinically important adverse reactions. These findings may facilitate individualized safety monitoring and optimize toxicity management in patients with NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1836198","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:25:37Z","timestamp":1785126337000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic toxicity and clinical prioritization of docetaxel combined with nintedanib for non-small cell lung cancer: a real-world safety analysis using the FAERS database"],"prefix":"10.3389","volume":"16","author":[{"given":"Qian","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Norinco General Hospital","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Norinco General Hospital","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Norinco General Hospital","place":["Xi\u2019an, Shaanxi, China"]},{"name":"The Center for Drug Safety and Policy Research, Xi\u2019an Jiaotong University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[{"name":"Zhuoxunda Technology Development Co., Ltd.","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanpeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xi\u2019an Rail Transit Group Co., Ltd. Operations Branch","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xifeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Norinco General Hospital","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","article-title":"The role of microenvironment in tumor angiogenesis","volume":"39","author":"Jiang","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2016.00068","article-title":"Focus on nintedanib in NSCLC and other tumors","volume":"3","author":"Manzo","year":"2016","journal-title":"Front Med (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.610903","article-title":"The role of anti-angiogenesis in the treatment landscape of non-small cell lung cancer - new combinational approaches and strategies of neovessel inhibition","volume":"8","author":"Daum","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-1018","article-title":"Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO","volume":"11","author":"Groh\u00e9","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0262","article-title":"Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma","volume":"15","author":"Groh\u00e9","year":"2019","journal-title":"Future Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2478\/raon-2023-0040","article-title":"Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis","volume":"57","author":"Ljubicic","year":"2023","journal-title":"Radiol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-3848(12)70016-6","article-title":"Side effects of anti-angiogenic drugs","volume":"129","author":"Elice","year":"2012","journal-title":"Thromb Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-3848(10)70014-1","article-title":"Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact","volume":"125","author":"Elice","year":"2010","journal-title":"Thromb Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.08.004","article-title":"Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy","volume":"148","author":"Reck","year":"2020","journal-title":"Lung Cancer"},{"key":"B19","unstructured":"2026"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug postmarketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1488725","article-title":"The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline","volume":"15","author":"Fusaroli","year":"2024","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3695101","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA Adverse Event Reporting System","volume":"2020","author":"Hu","year":"2020","journal-title":"J Diabetes Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/clep.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA Adverse Event Reporting System","volume":"14","author":"Shu","year":"2022","journal-title":"Clin Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.7967","article-title":"Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms","volume":"11","author":"Sakaeda","year":"2014","journal-title":"Int J Med Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200023060-00004","article-title":"A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database","volume":"23","author":"Lindquist","year":"2000","journal-title":"Drug Saf"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA Adverse Event Reporting System","volume":"19","author":"Cecco","year":"2024","journal-title":"Target Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.889088","article-title":"Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data","volume":"13","author":"Sauzet","year":"2022","journal-title":"Front Pharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.4_suppl_1.144s","article-title":"Paclitaxel and docetaxel combinations in non-small cell lung cancer","volume":"117","author":"Belani","year":"2000","journal-title":"Chest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2025.05.008","article-title":"Efficacy and safety of Nintedanib in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"73","author":"Cheema","year":"2025","journal-title":"Heart Lung"},{"key":"B35","article-title":"Phase I study of oral nintedanib combined with docetaxel in previously treated Japanese patients with advanced non-small cell lung cancer (NSCLC)","volume":"49","author":"Okamoto","year":"2013","journal-title":"Eur J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(16)31743-9","article-title":"Tumour growth over time in patients with advanced non-small cell lung cancer treated with nintedanib plus docetaxel or placebo plus docetaxel: analysis of data from the LUME-Lung 1 study","volume":"51","author":"Reck","year":"2015","journal-title":"Eur J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2021.12.010","article-title":"Real-world efficacy of nintedanib plus docetaxel after progression on immune checkpoint inhibitors: results from the ongoing, non-interventional VARGADO study","volume":"34","author":"Groh\u00e9","year":"2022","journal-title":"Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.01.001","article-title":"Thrombosis associated with angiogenesis inhibitors","volume":"22","author":"Elice","year":"2009","journal-title":"Best Pract Res Clin Haematology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2494688","article-title":"Thromboembolic and bleeding events associated with angiogenesis inhibitors in cancer patients","volume":"21","author":"Ma","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000492472","article-title":"Impact of epidermal growth factor receptor mutation on clinical outcomes of nintedanib plus docetaxel in patients with previously treated non-small cell lung cancer from the Korean Named Patient Program","volume":"96","author":"Hong","year":"2019","journal-title":"Oncology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00178","article-title":"The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approach","volume":"4","author":"Dawe","year":"2014","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu268","article-title":"A review of the management of elderly patients with non-small-cell lung cancer","volume":"26","author":"Blanco","year":"2015","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2011.597815","article-title":"Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events","volume":"29","author":"Wu","year":"2011","journal-title":"Cancer Invest"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40264-018-0703-x","article-title":"Effect of lawyer-submitted reports on signals of disproportional reporting in the Food and Drug Administration's Adverse Event Reporting System","volume":"42","author":"Rogers","year":"2019","journal-title":"Drug Saf"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00834-1","article-title":"The impact of litigation-associated reports on signal identification in the US FDA's Adverse Event Reporting System","volume":"42","author":"Mu\u00f1oz","year":"2019","journal-title":"Drug Saf"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1836198\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:25:38Z","timestamp":1785126338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1836198\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":48,"alternative-id":["10.3389\/fonc.2026.1836198"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1836198","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1836198"}}